Wa'el Hashad Wa'el Hashad, CEO, Longeveron Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2025.

From lifting military aid restrictions to delisting Baloch insurgents, Trump extended key political and security concessions ...

Pakistan and the US have agreed to deepen bilateral cooperation to tackle leading militant groups, including the Balochistan ...

NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration <s ...

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's ...

The EMA's CHMP said the single pivotal US trial could serve as the basis for a marketing authorization application in the EU.

This designation positions CELZ-201-DDT among a select group of therapies recognized for their potential to address serious medical conditions with high unmet need. Fast Track status enables the ...

Security forces killed on Tuesday at least three more terrorists during a sanitisation operation on the night of August 10 and 11 in the general area of Sambaza along the Pakistan-Afghanistan border, ...

RemeGen announced that it plans to submit a Biologics License Application (BLA) to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for primary ...

August 12, 2025BioRestorative Therapies, Inc. beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.41. Operator: Greetings. Welcome to the BioRestorative Therapies Second Quarter ...

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the ...